Moderna Signs EU Deal for Up to 24m mRESVIA Doses

Moderna has signed a joint procurement framework contract with the European Commission for up to 24 million doses of its mRESVIA respiratory syncytial virus (RSV) vaccine, giving member states access ahead of the 2026-2027 winter season. Announced on 9 July 2026, the contract was signed at the request of six unnamed member countries and runs for up to four years with no minimum order requirement.

mRESVIA is an mRNA vaccine that delivers genetic instructions to cells to trigger a protective antibody response against RSV. It was approved in Europe in August 2024 for adults aged 60 and over at risk of RSV-caused lower respiratory tract disease, with subsequent access for younger high-risk groups. Earlier this year, a European Medicines Agency committee recommended expanding the licence to all adults aged 18 and over, opening a significantly larger addressable population. RSV causes bronchitis, pneumonia and other severe lung complications and is responsible for more than 156,000 adult hospitalisations across Europe annually.

European commissioner Hadja Lahbib framed the procurement as strengthening member state preparedness ahead of the winter respiratory season and easing pressure on hospital capacity. The European move contrasts with a more hesitant regulatory position in the US, where policy shifts have reduced reliance on mRNA-based vaccines. The FDA widened mRESVIA’s use to all adults at increased risk of RSV-caused lower respiratory tract disease in June 2025 but has not extended a general recommendation. Moderna’s main competitors in the RSV vaccine market are GSK’s Arexvy and Pfizer’s Abrysvo, which remain the top-selling RSV vaccines globally.

The commercial signal cuts along two axes. On the market side, mRESVIA’s European procurement momentum tightens the competitive race against Arexvy and Abrysvo, particularly ahead of the potential 18+ label expansion. On the regulatory side, the widening gulf between EU and US positioning on mRNA-based vaccines is emerging as a strategic sourcing consideration for European public health procurement.

For the latest updates and in-depth insights into the world of Pharmaceutical, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!